General Growth Properties (GGP) Declares $0.19 Quarterly Dividend; 2.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
General Growth Properties (GGP) Tops Q1 FFO by 5c, Offers Guidance
May 2, 2016 4:06 PM EDTGeneral Growth Properties (NYSE: GGP) reported Q1 EPS of $0.40, $0.05 better than the analyst estimate of $0.35.
GUIDANCE:
General Growth Properties sees Q2 2016 FFO of $0.34-$0.36, versus the consensus of $0.36.
General Growth Properties sees FY2016 FFO of $1.52-$1.56, versus the consensus of... More
Ackman defends Valeant, hints at more changes
May 2, 2016 12:38 PM EDTBy Svea Herbst-Bayliss and Caroline Humer
BOSTON/NEW YORK (Reuters) - Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals (NYSE: VRX), ruling out any sale of the drug company's "crown jewel" assets but saying price cuts and even a new name may be in its future.
Ackman, whose Pershing Square Capital Management owns 9 percent of Valeant, predicted the company would turn around with the help of its new chief executive officer and by selling greater volumes of products instead of just raising the price of its drugs.
... More